Company intelligence / Profile preview

PharmAla Biotech

Ownership: Public · MDMA
Development stage: Preclinical

Overview

Two multi-national Phase 3 clinical trials for MDMA-assisted PTSD treatment have been successful. An FDA decision is anticipated as early as H2 2024. The company has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research ongoing at the University of Arkansas Medical School.

Therapeutic areas: Psychiatry
Modalities: MDMAMDXX class moleculesNovel Chemical Entities (NCEs)
Industry: Biotech

Drug pipeline

5 assets

APA-01

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

University of Arkansas Medical SchoolUniversity of WindsorUniversity of SydneyEmyria Ltd.

Beyond the preview

Go deeper on PharmAla Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmAla Biotech.

Explore the full profile